Top of this page
Skip navigation, go straight to the content

Our Science Pipeline

R&D pipeline


The UCB pipeline delivers:

  •  a promising portfolio targeting severe diseases and addressing unmet medical needs
  •  focus on neurological and immunological diseases
  •  more convenient and effective treatments for patients and specialists.
Small molecule drug / NCE


Antibody-based drug / NBE


  Indications Phase 1 Phase 2 Phase 3 Filed
bimekizumab (IL17AF)psoriasisphase 3
 psoriatic arthritisphase 3 half
 axial spondyloarthritis
phase 3 half
 hidradenitis suppurativa
phase 3 first quarter
padsevonil (PPSI)epilepsy – drug resistantphase 3 half
zilucoplan (C5)myasthenia gravisphase 3 three quarter
 otherphase 1
rozanolixizumab (FcRn)myasthenia gravisphase 3 half
 immune thrombocytopeniaphase 3 first quarter
 chronic inflammatory demyelinating polyneuropathy (CIDP)phase 2 half
dapirolizumab pegol (CD40L)*systemic lupus erythematosusphase 2
UCB0107 (Tau)Progressive Supranuclear Palsy (PSP)phase 1
UCB0599Parkinson's diseasephase 1 half
auto-inflammatory diseasesphase 1 half


In collaboration with Biogen